SMARCA4 is a haploinsufficient B cell lymphoma tumor suppressor that fine-tunes centrocyte cell fate decisions.

in Cancer cell by Qing Deng, Priya Lakra, Panhong Gou, Haopeng Yang, Cem Meydan, Matthew Teater, Christopher Chin, Wenchao Zhang, Tommy Dinh, Usama Hussein, Xubin Li, Estela Rojas, Weiguang Liu, Patrick K Reville, Atish Kizhakeyil, Darko Barisic, Sydney Parsons, Ashley Wilson, Jared Henderson, Brooks Scull, Channabasavaiah Gurumurthy, Francisco Vega, Amy Chadburn, Branko Cuglievan, Nader Kim El-Mallawany, Carl Allen, Christopher Mason, Ari Melnick, Michael R Green

TLDR

  • SMARCA4 is a gene that helps cells in the lymphoma (a type of cancer) do their job. The study found that when SMARCA4 is missing, it can cause the cells to become more likely to become cancerous. The study also found that when SMARCA4 is missing, it can cause the cells to become more likely to divide and grow. This could be important for understanding how to treat lymphoma.

Abstract

SMARCA4 encodes one of two mutually exclusive ATPase subunits in the BRG/BRM associated factor (BAF) complex that is recruited by transcription factors (TFs) to drive chromatin accessibility and transcriptional activation. SMARCA4 is among the most recurrently mutated genes in human cancer, including ∼30% of germinal center (GC)-derived Burkitt lymphomas. In mice, GC-specific Smarca4 haploinsufficiency cooperated with MYC over-expression to drive lymphomagenesis. Furthermore, monoallelic Smarca4 deletion drove GC hyperplasia with centroblast polarization via significantly increased rates of centrocyte recycling to the dark zone. Mechanistically, Smarca4 loss reduced the activity of TFs that are activated in centrocytes to drive GC-exit, including SPI1 (PU.1), IRF family, and NF-κB. Loss of activity for these factors phenocopied aberrant BCL6 activity within murine centrocytes and human Burkitt lymphoma cells. SMARCA4 therefore facilitates chromatin accessibility for TFs that shape centrocyte trajectories, and loss of fine-control of these programs biases toward centroblast cell-fate, GC hyperplasia and lymphoma.

Overview

  • The study focuses on SMARCA4, a gene that encodes one of two mutually exclusive ATPase subunits in the BRG/BRM associated factor (BAF) complex. The study tests the hypothesis that SMARCA4 loss biases towards centroblast cell-fate, GC hyperplasia, and lymphoma. The methodology used for the experiment includes mice with GC-specific Smarca4 haploinsufficiency and monoallelic Smarca4 deletion. The primary objective of the study is to understand the role of SMARCA4 in driving chromatin accessibility and transcriptional activation in the BRG/BRM associated factor (BAF) complex and how its loss biases towards centroblast cell-fate, GC hyperplasia, and lymphoma.

Comparative Analysis & Findings

  • The study compares the outcomes observed under different experimental conditions, specifically mice with GC-specific Smarca4 haploinsufficiency and monoallelic Smarca4 deletion. The results show that monoallelic Smarca4 deletion drives GC hyperplasia with centroblast polarization via significantly increased rates of centrocyte recycling to the dark zone. The study also identifies that loss of activity for TFs that are activated in centrocytes to drive GC-exit, including SPI1 (PU.1), IRF family, and NF-κB, phenocopies aberrant BCL6 activity within murine centrocytes and human Burkitt lymphoma cells. The key findings of the study suggest that SMARCA4 loss biases towards centroblast cell-fate, GC hyperplasia, and lymphoma.

Implications and Future Directions

  • The study's findings have significant implications for the field of research and clinical practice, as SMARCA4 is among the most recurrently mutated genes in human cancer, including ∼30% of germinal center (GC)-derived Burkitt lymphomas. The study suggests that SMARCA4 loss biases towards centroblast cell-fate, GC hyperplasia, and lymphoma, which could have important implications for the development of new therapies for these diseases. Future research directions could include exploring the role of SMARCA4 in other types of cancer and identifying potential therapeutic targets for SMARCA4 loss.
Read Full Article